Introduction
Chromosome translocations are present in the majority of acute lymphoblastic leukemias (ALLs) and play a critical role in leukemogenesis. 1 Identification of specific non-random translocations is an important component of leukemia classification and some abnormalities have implications for risk stratification and treatment assignment. 2 The 19p13.3 gene E2A (also termed TCF3) is the target of three known recurrent genomic rearrangements in ALL. The t(1;19)(q23;p13.3), which occurs in approximately 5% of cases, is the second most common translocation in ALL. 3, 4 E2A is fused to the chromosome 1 gene PBX1 in 90-95% of patients with a t(1;19). [5] [6] [7] [8] The remaining 5-10% of patients have translocations that appear identical by standard cytogenetics, but must have a different molecular abnormality as neither E2A nor PBX1 is involved. 9 The t(17;19)(q22;p13) occurs in Ͻ1% of ALLs and fuses E2A to the chromosome 17 gene HLF. 10, 11 A recently described cryptic inversion of chromosome 19 fuses E2A to the 19q13.4 gene FB1.
12 E2A-PBX1 and E2A-HLF are chimeric transcription factors that contain the same portion of E2A, including two transcriptional activation domains, fused to regions of PBX1 or HLF that contain unique DNA binding domains. E2A-FB1 contains the same region of E2A fused to varying portions of the novel FB1 protein, which does not contain identifiable protein motifs.
Several groups reported that children with ALL and a t(1;19) had an inferior prognosis when treated with relatively less intensive chemotherapy used in the 1980s. 13, 14 This adverse effect seems to be restricted to patients with E2A-PBX1 fusion and can be overcome with more intensive chemotherapy. [14] [15] [16] The t(1;19) occurs in both balanced and unbalanced forms. 17 Approximately one-third of patients have the balanced form, a simple reciprocal translocation that does not result in any net loss or gain of genetic material. 14, 16 The unbalanced type occurs more frequently and may arise by non-disjunction leading to loss of the der(1) and replacement with a second copy of the remaining normal chromosome 1. The unbalanced form can arise during clonal evolution, as the two types are observed simultaneously or metachronously in some patients. 15, 17, 18 Some groups have reported that patients with a balanced t(1;19) have a significantly worse prognosis than those with an unbalanced translocation, while others have not found significant differences in treatment outcome. 15, 16, 18 E2A abnormalities can be identified by several different techniques. Standard cytogenetic studies are routinely performed in patients with leukemia for purposes of risk stratification and treatment assignment. The t(1;19) and t (17;19) are detected readily by this approach, but it misses the cryptic inv(19) associated with E2A-FB1 fusion 12 and does not reveal which t (1;19) positive cases lack E2A-PBX1 fusion. Furthermore, informative karyotypes are not obtained from all leukemia patients due to culture failures and overgrowth of residual normal cells. The Pediatric Oncology Group, using a dedicated reference cytogenetics laboratory to determine karyotypes, showed that a t(1;19) was not detected in a quarter to one third of patients with E2A-PBX1 fusion. 19 It is unlikely that most local cytogenetics laboratories, less experienced in leukemia cytogenetics, are more successful than this. Molecular studies can also be used to identify patients with E2A translocations. Because almost all E2A rearrangements occur within a small genomic region, Southern blotting with E2A cDNA probes readily detects gene rearrangements in leukemias with E2A translocations. 5, 20, 21 Reverse-transcriptase polymerase chain reaction (RT-PCR) assays also have been developed to amplify E2A fusion transcripts produced by these three different rearrangements. 8, 9, 12, 21 However, these molecular-based techniques are not used widely in routine clinical practice.
Fluorescence in situ hybridization (FISH) is becoming readily available in most clinical cytogenetic laboratories and can be used to analyze dividing (metaphase) and non-dividing (interphase) cells. Several FISH-based approaches have been developed to identify gene fusion events produced by chromosome translocations, and specific assays have been described that detect almost all of the common translocations that are clinically important in acute leukemia. 22 A major exception is the t(1;19), which is the most common known translocation in acute leukemia for which a FISH assay has not been described. A FISH assay for E2A translocations would provide information important for classification and initial clinical management of patients with ALL. It would also allow the E2A status of individual cells to be determined, which should help answer clinical problems that can arise during therapy.
In this report, we describe a 'split signal' FISH assay that reliably identifies E2A translocations and accurately distinguishes between balanced and unbalanced variants in metaphase and interphase cells from cell lines and patient samples with a t(1;19) or t (17;19) . This assay detected E2A translocations in 8/8 patients with a t(1;19) and known E2A-PBX1 fusion, 2/2 patients with a t(17;19), one of whom was previously shown to have E2A-HLF fusion, and was negative in 10/10 patients that lacked a t(1;19) or t (17;19) . Analysis of the 10 patients with E2A translocations showed that clonal microheterogeneity is common, and that most patients have mixtures of cells with balanced and unbalanced variants of the t(1; 19) , indicating that this distinction may represent two ends of a continuum, rather than distinct biological entities. We also identified one cell line and three patients with variant t(1;19)s that we demonstrate do not involve E2A. This assay should have widespread clinical utility, will be important for translational research studies involving E2A translocations, and will allow the uncovering of other genetic abnormalities affecting this region of chromosome 19, as evidenced by the finding of deletions in the region including E2A in one ALL patient sample and one ALL cell line and the discovery of an E2A translocation involving a previously undescribed partner chromosome.
Materials and methods

Specimens
We analyzed a panel of six ALL cell lines with and without E2A translocations. Positive cell lines included RCH-ACV and HAL-01, which respectively contain balanced (1;19)(q23;p13) and (17;19)(q21;p13) translocations (kindly provided by Drs Ram Seshadri and Kazuma Ohyashiki). 23, 24 Negative cell lines were Jurkat, Nalm6, REH and TS-2. TS-2 (kindly provided by Drs Yoshinari and Imaizumi, Tohoku University, Sendai, Japan) contains a t(1;19)(q23;p13), but lacks E2A gene rearrangements and E2A-PBX1 fusion transcripts. 25 Twentythree primary ALL patient samples that had been cryopreserved (for up to 12 years) or stored as archived fixed cell pellets were obtained from the leukemia cell bank of The Children's Hospital and The Colorado Genetics Laboratory, Denver, CO. Twenty-one of these samples were obtained at initial diagnosis, one at the time of induction failure (No. 3709), and one at first bone marrow relapse (No. 3008). These studies were performed under a research protocol approved by the Combined Institutional Review Boards (COMIRB) of the University of Colorado Health Sciences Center and The Children's Hospital.
E2A gene rearrangements and E2A-PBX1 and E2A-HLF fusion transcripts were detected by Southern blotting and RT-PCR as described previously. 8, 19, 21 For patient samples, cytogenetic assays were routinely performed in The Colorado Genetics Laboratory at the time of initial diagnosis using previously described procedures. 26 Karyotypes were reviewed by one of the authors (L McGavran) and described according to the International System for Cytogenetic Nomenclature (ISCN, 1995) . 27 
FISH
Cosmids and bacterial artificial chromosomes (BACs) used in this study were provided by the human chromosome 19 mapping group at Lawrence Livermore National Labs (LLNL), which has generated an integrated physical map of human chromosome 19. 28 Cosmids from the chromosome 19-specific libraries LL19NC02 ('F' library) and LL19NC03 ('R' library) and BACs from the Caltech BAC library CIT978SKB 29 were selected based upon their predetermined location along chromosome 19. A current map of this region is available at http://bbrp.llnl.gov/genome/genome.html. FISH studies performed with normal controls confirmed the chromosomal localization and supported the selection of these clones. Cosmid and BAC DNA were isolated using commercial kits as suggested by the manufacturer (Qiagen, Valencia, CA, USA).
To prepare slides for FISH, cultured cells were harvested with the addition of colcemid (0.02 g/ml final concentration) for mitotic arrest and ethidium bromide (5 g/ml final concentration) for chromosome elongation for 1-3 h. Hypotonization was performed with a 0.075 M KCl solution, and a 3:1 mixture of methanol and glacial acetic acid was used for fixation. Cell suspensions were dropped on to microscope slides and aged overnight at room temperature, followed by a 30 min incubation in 2 × SSC (1 × SSC is 0.15 M NaCl with 0.015 M sodium citrate) at 37°C. Frozen cells from archived specimens were thawed, washed three times in Hank's balanced salt solution (Gibco BRL, Grand Island, NY, USA), suspended in RPMI media (Gibco BRL) with 15% fetal bovine serum (Irvine Scientific, Irvine, CA, USA) and incubated at 37°C overnight. The delayed-direct harvest cells were hypotonized, fixed, dropped on to slides, and treated as described above. Slides were then digested in RNase (100 g/ml in 1 × PBS) and in pepsin (0.01% in 0.01 N HCl), fixed in formaldehyde (4% in 2 × SSC), dehydrated, and denatured in 70% formamide/2 × SSC at 72°C for 2-10 min.
To prepare the probe cocktail for FISH detection of E2A disruption (Figure 1 ), 1 g of DNA from four cosmids located centromeric to the E2A breakpoint cluster region (R29335, F15900, R27731 and R31449) was labeled individually by nick translation with SpectrumGreen d-UTP (Vysis, Downers Grove, IL, USA). Similarly, 1 g of DNA from cosmid R30538 and BAC CIT978SKB 25B13 (LLNL clone No. 38864), which are located telomeric to E2A and overlap partially, was directly labeled with SpectrumRed d-UTP (Vysis). The labeled DNAs were pooled together and co-precipitated with a 40-fold excess of salmon sperm DNA and a 20-fold excess of Cot-1 DNA, dissolved in a commercially prepared hybridization buffer (Chroma Hyb; Quantum Biotechnologies, Quebec, Canada) with 1% Tween-20, denatured at 75°C, and incubated at 37°C for 20 min to pre-anneal the Cot-1 DNA
Figure 1
Location of cosmids used for FISH. The region surrounding E2A on chromosome 19 is depicted schematically. The E2A gene and its breakpoint cluster region (bcr) are located within cosmid R27377. The centromeric probe cocktail consists of the four cosmids and the telomeric probe cocktail consists of the cosmid and BAC listed on the figure. Approximate distances from 19pTel are given in megabases (Mb) at the bottom.
to repetitive sequences. Following this, one-tenth of the probe mixture was applied to selected areas of slides containing fixed cells, which were then covered with glass coverslips, sealed with rubber cement, and allowed to hybridize for 2-3 days at 37°C. Post-hybridization, three 50% formamide/ 2 × SSC, one 2 × SSC, and one 2 × SSC/0.1% NP-40 washes were performed sequentially at 46°C for 6 min each. DAPI (4′6-amidino-2-phenylindole) II (Vysis) was used for counterstaining. A similar procedure was used for hybridizations performed with individual cosmids containing the E2A breakpoint cluster region (F23667 and R27377). Slides were examined visually on an Olympus (Melville, NY, USA) BX60 epifluorescence microscope with interference filter sets for red (Texas Red, Sulforhodamine 101 sulfonyl chloride), green {FITC, Fluorescein (3′,6′-Dihydroxyspro[isobenzofuranl (3H), 9′-[9H] xanthen]-3-one)}, and blue (DAPI), as well as dual band pass (Texas Red + FITC), and triple band pass (Texas Red + FITC + DAPI) color filters (Chroma Technology, Brattleboro, VT, USA). Samples were analyzed in a blinded manner without knowledge of the karyotype or molecular studies. At least two hundred interphase cells were scored for each sample, with the addition of metaphase cell data when possible. The characteristic fluor pattern for each cell analyzed per specimen was individually recorded and subsequently classified according to genotype. For documentation, gray-color images were acquired with a cooled charged capture device (CCD) camera (Sensys, Photometrics; Tucson, AZ, USA) and merged using the Vysis Quips software.
Results
Single cosmids containing the E2A breakpoint cluster region are split in metaphase FISH in RCH-ACV
The E2A gene, which is located ෂ1.5 megabases (Mb) from the telomere of the p arm of chromosome 19 (19ptel) , was previously shown to be contained within two highly overlapping independent cosmids, F23667 and R27377. 28 GenBank searches with E2A cDNA sequence reveal that the first two exons of E2A are located within cosmid R29335 (GenBank accession No. AC006274), which is located immediately centromeric to R27377 (GenBank accession No. AC005321) with an approximately 2.6 kb overlap (Figure 1 ). The remaining E2A exons are contained in R27377 with the major 3.3 kb breakpoint cluster region, within which almost all t(1;19) and t(17;19) breakpoints occur, located roughly in the middle of this cosmid (nucleotides 14 444 to 17 731 of 38 937) between exons 15 and 16 (which have previously been termed exons 13 and 14) . Metaphase slides from the t(1; 19) positive RCH-ACV cell line and negative control samples were hybridized with cosmids R27377 and F23667 individually. In control samples, we observed two signals with these cosmids, one on each copy of chromosome 19. In contrast, three signals were seen with each cosmid in RCH-ACV: one on the normal chromosome 19, one on the der (19) , and one on the der(1) (data not shown). These data confirmed that the E2A breakpoint cluster region occurs within cosmids F23667 and R27377.
A two-color split signal FISH assay detects E2A abnormalities in cell lines
Next, we sought to develop a set of probes that could create a robust metaphase and interphase FISH assay to detect E2A Leukemia translocations in clinical samples. As there are several molecular abnormalities that target E2A, we decided to develop a generic split signal FISH assay that should detect any of the known E2A abnormalities. To do this, we selected clones located immediately centromeric and telomeric to cosmid R27377. To increase sensitivity and specificity in interphase FISH assays, we pooled four cosmids to generate the centromeric probe and used a cosmid and a BAC as the telomeric probe. The telomeric probe cocktail covers the region from ෂ1.31 to 1.49 Mb from 19ptel and the centromeric cocktail the region from ෂ1.53 to 3.4 Mb from 19ptel (Figure 1 ). Using these probes, a normal chromosome 19 should produce a fused red-green signal. A translocation that interrupts E2A should result in split red and green signals with the centromeric probe cocktail hybridizing to the der(19) and the telomeric probe cocktail hybridizing to the derivative chromosome containing the translocation partner gene (Figure 2a) .
Metaphase spreads from normal individuals hybridized with these probe cocktails showed two intense fused red-green signals at 19p13 (Figure 2b ). For RCH-ACV, we observed one fused red-green signal on the normal chromosome 19, a single red signal on the der(1), and a single green signal on the der (19) (Figure 2c ). HAL-01 also showed a split pattern with the red signal on the der(17) in this case ( Figure 2d ). Next, we performed interphase FISH on slides freshly prepared from cell lines and normal individuals. As shown in Figure 2b- Table 1 ). We analyzed 10 ALL patients that lacked a t(1;19) or t(17;19) by both standard cytogenetics and Southern blotting or RT-PCR. For nine of these cases, 89-99% of cells contained two fused red-green signals (Figure 2e ) and р1% contained split individual red or green signals. Interestingly, the remaining case (No. 3660) had a karyotype that included an add(19)(p13.3) and showed only a single fused signal in 73% of cells. We analyzed samples from eight patients that had a t(1;19) identified by standard cytogenetics, four of whom had a balanced t(1;19) and four an unbalanced t(1;19); all eight had E2A gene rearrangements and/or expressed E2A-PBX1 fusion transcripts. We also analyzed two ALL patients who had a t(17;19) detected by routine cytogenetic analyses, one of whom has previously been shown to express type II E2A-HLF fusion tran-
Analysis of primary leukemias via interphase FISH
Figure 2
Identification of E2A translocations and distinguishing between balanced and unbalanced variants via FISH. (a) The split apart FISH assay is depicted schematically. On the left an ideogram of normal chromosomes 1 and 19 is shown with the probe cocktails, depicted as red and green signals, hybridizing to 19p13 flanking the E2A gene. The expected interphase FISH hybridization pattern is shown below. On the right the der(1) and der(19) chromosomes resulting from a balanced t(1;19)(q23;p13) are shown. In this case the green signal will hybridize to the der(19) and the red signal to the der(1), giving the interphase FISH hybridization pattern depicted below. 
Cell lines RCH-ACV 
Ͻ1
1 add(9)(p21),add(10)(q22) [22] /46,XY [6] 3401 46,XX,t(1;19)(q23;p13) [9] /46,XX [11] E2A-Rearranged (19) E2A-Rearranged signals denote the region telomeric to E2A which is translocated to the der(partner) chromosome. A cell without E2A or chromosome 19 abnormalities has a 2F hybridization pattern, a cell with a balanced t(1;19) or t(17;19) has a 1F/1G/1R pattern and a cell with an unbalanced translocation has a 1F/1G pattern. ND, not done; F, fused; G, green; R, red.
scripts. 21 Insufficient material was available from the other patient with a t(17;19) to perform molecular studies. As expected, these patient samples contained an admixture of cells with two fused signals, presumably representing residual non-leukemic cells. Each case clearly had an E2A translocation, with 37-91% of cells showing a hybridization pattern indicative of the type of translocation (balanced or unbalanced) identified by G-banding. Balanced translocations were detected by standard cytogenetics in four patients with a t(1;19) and one with a t (17;19) ; the majority of abnormal cells in each of these cases had a balanced translocation FISH pattern (one fused red-green, one green and one red signal) with the E2A probe cocktail (Figure 2f) . Similarly, four patients with a t(1;19) and one with a t(17;19) had an unbalanced translocation identified by G-banding and the majority of abnormal cells in each case had an unbalanced hybridization pattern via FISH with retention of the der (19) and loss of the der (1) or der(17) (1 fused red-green, one green and no red signal; Figure 2g ).
We analyzed one hyperdiploid ALL case (No. 3639) that had a t(1;19)(q23;p13) but lacked E2A gene rearrangements and E2A-PBX1 fusion transcripts. Leukemic cells from this patient expressed CD34 and thus did not conform to the typical immunophenotype associated with E2A-PBX1 fusion. 19 Metaphase FISH with chromosome 1 and 19 paint probes confirmed that a translocation between chromosomes 1 and 19 had occurred (data not shown). We observed two fused red-green signals in this case, confirming that this variant t(1;19) did not interrupt E2A (Figure 2h) 
Clonal heterogeneity with respect to balanced and unbalanced E2A translocations is common
Currently, it is not known if balanced and unbalanced E2A translocations represent two distinct entities or opposite ends of a continuum. Because of this, we looked closely to determine if patients with unbalanced E2A translocations had a subclone of cells that had a balanced translocation and vice versa (Table 1) . We found this to be the true for at least six of 10 patients with E2A translocations. To appreciate this, it is critical to examine the background level of signal loss. Among the 19 normal controls (n = 5), cell lines (n = 4) and patients (n = 10) without 19p13 translocations, only one case had more than 1% of cells with a hybridization pattern consistent with a balanced or unbalanced E2A translocation, case No. 3660 with 2% of cells having one fused, one green, and one red signal. Two of the four patients with a balanced t (1;19) (19) that fuses E2A to FB1, we anticipate that our FISH assay should readily identify this abnormality in both metaphase and interphase cells. Based on these factors, we believe that these reagents will have substantial clinical utility.
Several other important observations derive from this study. First, no patient with an E2A translocation had more than 1% of cells that lost the der (19) , confirming the critical importance of the E2A-PBX1 and E2A-HLF fusion proteins. Second, we observed clonal heterogeneity in more than half of the patients with E2A translocations. While a substantial majority of abnormal cells in each patient had either a balanced or unbalanced translocation via FISH, 6/10 also had a subclone with the opposite abnormality. These data support the logical assumption that the unbalanced form arises from the balanced form via non-disjunction, as one could not re-establish cells with a balanced translocation following a primary unbalanced rearrangement. The clinical significance of the distinction between unbalanced and balanced (1;19) translocations remains controversial 15, 16, 18 and merits further study, which should be facilitated by these reagents.
There are several obvious differences between these two variants of the t(1;19). Patients with a balanced translocation retain the reciprocal PBX1-E2A fusion gene on the der(1), while those with an unbalanced translocation lose this fusion gene. This seems unlikely to be of any clinical significance because PBX1 is not transcribed in lymphoid cells and there is no expression of PBX1-E2A fusion transcripts in cell lines or patients with a balanced t (1;19) . 20 Although patients with a balanced translocation do not have any net genetic gains or losses, those with an unbalanced t(1;19) are trisomic for the region of chromosome 1q telomeric to PBX1, monosomic for the region of chromosome 19 telomeric to E2A, and presumably have uniparental isodisomy for the non-trisomic portion of chromosome 1. While it seems counter to the normal process of clonal selection for a more clinically aggressive leukemia (balanced) to evolve into a less aggressive form (unbalanced) with accompanying changes in gene copy, it is possible that an unbalanced t(1;19) is a marker for leukemias that respond well to the type of intensive chemotherapy currently administered to patients with ALL.
An unexpected finding of our study was deletion of the region surrounding E2A in Nalm6 and one patient sample. The patient had del(11)(q23),add(19)(p13) detected via classical cytyogenetics and could have an unbalanced translocation involving a gene centromeric to E2A. This does not appear to be an MLL translocation as FISH showed that one copy of MLL was intact and one was deleted (LM and LM, unpublished data). Another possibility is that these rearrangements may be unmasking mutations or producing haplo-insufficiency in a tumor suppressor gene located in this region of the short arm of chromosome 19. The data presented here and in other studies from our laboratory (TB and SPH, unpublished data) show that both of these deletions extend Ͼ2 Mb centromeric and Ͼ500 kb telomeric to E2A. E2A itself is an excellent candidate tumor suppressor gene, as most E2A knockout mice that survive past 3 months of age later develop lymphomas. 30, 31 We also note that these reagents should be useful for the identification of additional E2A translocations and have recently used them to identify an E2A translocation involving a previously undescribed partner chromosome in a child with ALL (LM, LM, TB and SPH, unpublished data). Thus, in addition to their substantial clinical utility, these reagents will facilitate additional translational research studies pertaining to E2A translocations and will prove useful for identification and characterization of other somatic genetic changes involving this region of 19p13 in human leukemias.
